Pneumococcal Vaccination for Healthy Adults Turning 65
For an otherwise healthy adult turning 65 with no COPD or other high-risk conditions, administer a single dose of either PCV20 alone OR PCV15 followed by PPSV23 at least 1 year later 1.
Vaccination Schedule Options
You have two equally acceptable pathways:
Option A: Single-Vaccine Approach
- Administer PCV20 as a single dose
- This is the simpler option requiring only one vaccine visit
- Provides complete pneumococcal vaccination in one shot
Option B: Two-Vaccine Sequential Approach
- Administer PCV15 first
- Then give PPSV23 ≥1 year after the PCV15 dose
- This requires two separate visits but covers additional serotypes through PPSV23
If They've Never Been Vaccinated
For vaccine-naïve adults at age 65 with no immunocompromising conditions, CSF leak, or cochlear implant, both options above apply equally 1. The key distinction is that healthy 65-year-olds without risk factors get a longer interval (≥1 year) between PCV15 and PPSV23, compared to the 8-week interval used for high-risk individuals.
Important Clinical Distinctions
COPD is NOT listed among the conditions requiring the accelerated 8-week interval between PCV15 and PPSV23. The conditions requiring shorter intervals are specifically: chronic renal failure, asplenia, immunodeficiency, malignancy, HIV, immunosuppression, leukemia, lymphoma, multiple myeloma, nephrotic syndrome, sickle cell disease, and solid organ transplant 1.
While COPD is mentioned as a chronic lung disease that warrants pneumococcal vaccination in adults aged 19-64 years 1, once someone reaches age 65, the age-based recommendation supersedes the chronic condition categories for scheduling purposes. At 65+, all adults get vaccinated regardless of underlying conditions, and those without the specified high-risk immunocompromising conditions follow the standard 1-year interval schedule.
Recent Guideline Updates
Note that as of October 2024, ACIP expanded recommendations to include all adults ≥50 years 2. However, for your specific question about someone turning 65, the 2023 ACIP guidelines 1 provide the definitive framework, which remains current for this age group.
Practical Implementation
- Choose based on availability and patient preference: PCV20 offers simplicity; PCV15+PPSV23 offers broader serotype coverage
- Document clearly which vaccine was given to guide any future vaccination decisions
- No need to wait if they're turning 65 today—vaccinate now
- If prior vaccination history is unknown, treat as vaccine-naïve and follow the schedules above 1